Comparison of Characteristics and Outcomes of Patients Undergoing Saphenous Vein Graft Stenting Who Were or Were Not nrolled in the Stenting of Saphenous Vein Grafts andomized Controlled Trial

Tesfaldet T. Michael, Neeraj Badhey, Subhash Banerjee, Mmanouil S. Brilakis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective We sought to compare the characteristics and outcomes of patients who were enrolled versus those who were not enrolled in the Stenting of Saphenous Vein Grafts (SOS) randomized controlled trial. Methods and esults We identified all patients who underwent saphenous vein graft stenting during the SOS Trial enrollment period (May 2005 and October 2007) at our institution. Baseline characteristics and clinical outcomes were compared between patients who were versus those who were not enrolled in SOS. Of the 97 patients who underwent saphenous vein graft stenting during the study period, 62 patients (64%) were enrolled in SOS. In the enrolled group, 62 patients with 91 lesions were randomized to a bare metal stent (BMS) (n = 39) or paclitaxel-eluting stent (n = 41). In the nonenrolled group, 35 patients with 44 lesions received a drug-eluting stent (DS) (n = 27) or BMS (n = 8). During a median follow-up period of 2.66 years, nonenrolled patients had higher mortality (31.4% vs 14.5%, P = 0.039), but lower rates of myocardial infarction (5.7% vs 32.3%, P = 0.005) and target vessel failure (37% vs 61.3%, P = 0.023). Overall, patients who received DS had lower incidence of myocardial infarction, target lesion revascularization, target vessel failure and major adverse cardiac events, and similar mortality compared with the BMS group. Conclusions Compared with nonenrolled patients, those who were enrolled in SOS had lower mortality. Patients receiving DS had better outcomes than those receiving BMS in both groups.

Original languageEnglish (US)
Pages (from-to)259-266
Number of pages8
JournalJournal of Investigative Medicine
Volume59
Issue number2
DOIs
StatePublished - 2011

Fingerprint

Stents
Saphenous Vein
Grafts
Transplants
Metals
Drug-Eluting Stents
Pharmaceutical Preparations
Mortality
Myocardial Infarction
Paclitaxel
Randomized Controlled Trials

Keywords

  • bare-metal stent
  • drug-eluting stent
  • external validity
  • Key Words saphenous vein graft
  • percutaneous coronary intervention
  • randomized controlled trial

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{e311d5102acb4a4293eed47d2ed70da4,
title = "Comparison of Characteristics and Outcomes of Patients Undergoing Saphenous Vein Graft Stenting Who Were or Were Not nrolled in the Stenting of Saphenous Vein Grafts andomized Controlled Trial",
abstract = "Objective We sought to compare the characteristics and outcomes of patients who were enrolled versus those who were not enrolled in the Stenting of Saphenous Vein Grafts (SOS) randomized controlled trial. Methods and esults We identified all patients who underwent saphenous vein graft stenting during the SOS Trial enrollment period (May 2005 and October 2007) at our institution. Baseline characteristics and clinical outcomes were compared between patients who were versus those who were not enrolled in SOS. Of the 97 patients who underwent saphenous vein graft stenting during the study period, 62 patients (64{\%}) were enrolled in SOS. In the enrolled group, 62 patients with 91 lesions were randomized to a bare metal stent (BMS) (n = 39) or paclitaxel-eluting stent (n = 41). In the nonenrolled group, 35 patients with 44 lesions received a drug-eluting stent (DS) (n = 27) or BMS (n = 8). During a median follow-up period of 2.66 years, nonenrolled patients had higher mortality (31.4{\%} vs 14.5{\%}, P = 0.039), but lower rates of myocardial infarction (5.7{\%} vs 32.3{\%}, P = 0.005) and target vessel failure (37{\%} vs 61.3{\%}, P = 0.023). Overall, patients who received DS had lower incidence of myocardial infarction, target lesion revascularization, target vessel failure and major adverse cardiac events, and similar mortality compared with the BMS group. Conclusions Compared with nonenrolled patients, those who were enrolled in SOS had lower mortality. Patients receiving DS had better outcomes than those receiving BMS in both groups.",
keywords = "bare-metal stent, drug-eluting stent, external validity, Key Words saphenous vein graft, percutaneous coronary intervention, randomized controlled trial",
author = "Michael, {Tesfaldet T.} and Neeraj Badhey and Subhash Banerjee and Brilakis, {Mmanouil S.}",
year = "2011",
doi = "10.2310/JIM.0b013e318207066c",
language = "English (US)",
volume = "59",
pages = "259--266",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Comparison of Characteristics and Outcomes of Patients Undergoing Saphenous Vein Graft Stenting Who Were or Were Not nrolled in the Stenting of Saphenous Vein Grafts andomized Controlled Trial

AU - Michael, Tesfaldet T.

AU - Badhey, Neeraj

AU - Banerjee, Subhash

AU - Brilakis, Mmanouil S.

PY - 2011

Y1 - 2011

N2 - Objective We sought to compare the characteristics and outcomes of patients who were enrolled versus those who were not enrolled in the Stenting of Saphenous Vein Grafts (SOS) randomized controlled trial. Methods and esults We identified all patients who underwent saphenous vein graft stenting during the SOS Trial enrollment period (May 2005 and October 2007) at our institution. Baseline characteristics and clinical outcomes were compared between patients who were versus those who were not enrolled in SOS. Of the 97 patients who underwent saphenous vein graft stenting during the study period, 62 patients (64%) were enrolled in SOS. In the enrolled group, 62 patients with 91 lesions were randomized to a bare metal stent (BMS) (n = 39) or paclitaxel-eluting stent (n = 41). In the nonenrolled group, 35 patients with 44 lesions received a drug-eluting stent (DS) (n = 27) or BMS (n = 8). During a median follow-up period of 2.66 years, nonenrolled patients had higher mortality (31.4% vs 14.5%, P = 0.039), but lower rates of myocardial infarction (5.7% vs 32.3%, P = 0.005) and target vessel failure (37% vs 61.3%, P = 0.023). Overall, patients who received DS had lower incidence of myocardial infarction, target lesion revascularization, target vessel failure and major adverse cardiac events, and similar mortality compared with the BMS group. Conclusions Compared with nonenrolled patients, those who were enrolled in SOS had lower mortality. Patients receiving DS had better outcomes than those receiving BMS in both groups.

AB - Objective We sought to compare the characteristics and outcomes of patients who were enrolled versus those who were not enrolled in the Stenting of Saphenous Vein Grafts (SOS) randomized controlled trial. Methods and esults We identified all patients who underwent saphenous vein graft stenting during the SOS Trial enrollment period (May 2005 and October 2007) at our institution. Baseline characteristics and clinical outcomes were compared between patients who were versus those who were not enrolled in SOS. Of the 97 patients who underwent saphenous vein graft stenting during the study period, 62 patients (64%) were enrolled in SOS. In the enrolled group, 62 patients with 91 lesions were randomized to a bare metal stent (BMS) (n = 39) or paclitaxel-eluting stent (n = 41). In the nonenrolled group, 35 patients with 44 lesions received a drug-eluting stent (DS) (n = 27) or BMS (n = 8). During a median follow-up period of 2.66 years, nonenrolled patients had higher mortality (31.4% vs 14.5%, P = 0.039), but lower rates of myocardial infarction (5.7% vs 32.3%, P = 0.005) and target vessel failure (37% vs 61.3%, P = 0.023). Overall, patients who received DS had lower incidence of myocardial infarction, target lesion revascularization, target vessel failure and major adverse cardiac events, and similar mortality compared with the BMS group. Conclusions Compared with nonenrolled patients, those who were enrolled in SOS had lower mortality. Patients receiving DS had better outcomes than those receiving BMS in both groups.

KW - bare-metal stent

KW - drug-eluting stent

KW - external validity

KW - Key Words saphenous vein graft

KW - percutaneous coronary intervention

KW - randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=85008262951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008262951&partnerID=8YFLogxK

U2 - 10.2310/JIM.0b013e318207066c

DO - 10.2310/JIM.0b013e318207066c

M3 - Article

C2 - 21200334

AN - SCOPUS:85008262951

VL - 59

SP - 259

EP - 266

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 2

ER -